Form 4: Ligand Pharmaceuticals Director Stephen Sabba Increases Equity Holdings Through RSU and Stock Option Grants

Ligand Pharmaceuticals Inc. Director Stephen L. Sabba was granted 1,209 restricted stock units and 5,783 non-qualified stock options on June 6, 2025, as part of his compensation.

Summary

• Stephen L. Sabba, a Director of Ligand Pharmaceuticals Inc. (LGND), acquired additional equity interests in the company.
• On June 6, 2025, Mr. Sabba was granted 1,209 restricted stock units (RSUs), each representing a contingent right to receive one share of the company's common stock.
• These RSUs were granted by the Board of Directors at their annual meeting on June 6, 2025, and will fully vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date.
• Following this transaction, Mr. Sabba beneficially owns 33,793 shares of common stock.
• Additionally, on June 6, 2025, Mr. Sabba was granted 5,783 non-qualified stock options with an exercise price of $105.99 per share.
• These stock options also vest on the earlier of the next annual meeting of stockholders or the first anniversary of the grant date and have an expiration date of June 6, 2035.
• Following this transaction, Mr. Sabba beneficially owns 5,783 non-qualified stock options.

Sentiment

Score: 7

Explanation: The document reports a routine equity compensation grant to a director, which is a positive sign of alignment between management and shareholders, but does not contain information that would significantly alter the company's financial outlook or operations.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• The acquisition of equity by a director demonstrates continued commitment and confidence in the company's future.

Future Outlook

The vesting schedule for the RSUs and stock options indicates that they will fully vest on the earlier of the next annual meeting of the Company stockholders following the grant date or on the first anniversary of the date of grant, implying a future commitment period for the director.

Industry Context

This Form 4 filing details an equity grant to a director, which is a standard practice in the pharmaceutical and biotechnology industries to compensate and incentivize executive and board members. Such grants are common mechanisms to align the interests of directors with long-term shareholder value creation.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to board members is a common compensation practice across publicly traded companies, including those in the pharmaceutical sector.
• While specific grant sizes and vesting terms vary by company size, performance, and compensation philosophy, this type of equity-based compensation is standard for attracting and retaining qualified directors.
• Without specific compensation benchmarks for Ligand Pharmaceuticals' peer group, a direct quantitative comparison is not feasible from this document alone.

Corporate Governance

Related Party Transactions

• The grant of equity (restricted stock units and stock options) to Stephen L. Sabba, a Director of Ligand Pharmaceuticals Inc., constitutes a related party transaction, which is a standard form of compensation and is disclosed as required by SEC regulations.

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated.
• Customers: No direct impact on customers is indicated.
• Suppliers: No direct impact on suppliers is indicated.
• Creditors: No direct impact on creditors is indicated.

Next Steps

• The restricted stock units and stock options will vest on the earlier of the next annual meeting of the Company stockholders following the grant date or on the first anniversary of the date of grant.

Key Dates

Recommendation

Keywords

Ligand Pharmaceuticals, LGND, Stephen L. Sabba, SEC Form 4, beneficial ownership, restricted stock units, RSUs, stock options, equity grant, director compensation, insider transaction